3817 |
Revisiting Anticoagulants: Why Dual Pathway Inhibition Is Not Back? |
Roxana Mehran |
Apr. 21. 16 |
3816 |
ISR: All or Selective Use? |
Lawrence A. Garcia |
Apr. 21. 16 |
3815 |
CTO: All or Selective Use? |
Young-Guk Ko |
Apr. 21. 16 |
3814 |
Calcific Lesion: All or Selective Use? |
Ravish Sachar |
Apr. 21. 16 |
3813 |
Class Effect of DCB? |
Seung-Whan Lee |
Apr. 21. 16 |
3812 |
Next-Generation DCBs: "Make It Different?" |
Mark W. Burket |
Apr. 21. 16 |
3811 |
When AF & ACS Collide: Many Regimens, Little Solutions! |
Freek W.A. Verheugt |
Apr. 21. 16 |
3810 |
DAPT and Beyond 12 Months: Which One and How Long? |
Sorin Brener |
Apr. 21. 16 |
3809 |
Pretreatment with P2Y12 Inhibitors: When Selective vs. Routine Is Used? |
David Joel Cohen |
Apr. 21. 16 |
3808 |
Drug-Eluting Stents vs. Bioresorbable Vascular Scaffolds: Is Newer Better? |
Gregg W. Stone |
Apr. 21. 16 |